Tag Archive for: subcutaneous dosing

While the Alzheimer’s space awaits data from the Phase III trial of Eli Lilly’s donanemab, the company unveiled the first clinical data from another anti-amyloid antibody at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2023).